BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26506264)

  • 1. p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB
    Cell Cycle; 2015; 14(22):3602-12. PubMed ID: 26506264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
    J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.
    Chen S; Xing H; Li S; Yu J; Li H; Liu S; Tian Z; Tang K; Rao Q; Wang M; Wang J
    Leuk Res; 2015 Sep; 39(9):976-83. PubMed ID: 26159495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
    Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
    Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleostemin knocking-down causes cell cycle arrest and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells via p53 and p21Waf1/Cip1 up-regulation.
    Rahmati M; Moosavi MA; Zarghami N
    Hematology; 2014 Dec; 19(8):455-62. PubMed ID: 24628257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells.
    Zhuang Y; Lu Y; Li D; Sun N; Ju X
    Oncol Rep; 2015 Mar; 33(3):1319-25. PubMed ID: 25524659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
    Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
    Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
    Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
    Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.
    Kuang SQ; Fang Z; Zweidler-McKay PA; Yang H; Wei Y; Gonzalez-Cervantes EA; Boumber Y; Garcia-Manero G
    PLoS One; 2013; 8(4):e61807. PubMed ID: 23637910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Histone deacetylase inhibitors cause the TP53-dependent induction of p21/Waf1 in tumor cells carrying mutations in TP53].
    Kovalev RA; Shtam TA; Karelov DV; Burdakov VS; Volnitskiy AV; Makarov EM; Filatov MV
    Tsitologiia; 2015; 57(3):204-11. PubMed ID: 26021170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.
    Bajbouj K; Mawrin C; Hartig R; Schulze-Luehrmann J; Wilisch-Neumann A; Roessner A; Schneider-Stock R
    J Neurooncol; 2012 May; 107(3):503-16. PubMed ID: 22270849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.
    Habold C; Poehlmann A; Bajbouj K; Hartig R; Korkmaz KS; Roessner A; Schneider-Stock R
    J Cell Mol Med; 2008 Apr; 12(2):607-21. PubMed ID: 18419600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
    Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
    BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.
    Shao N; Zou J; Li J; Chen F; Dai J; Qu X; Sun X; Ma D; Ji C
    Leuk Lymphoma; 2012 Sep; 53(9):1769-78. PubMed ID: 22303878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
    Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
    Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
    Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
    PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells.
    Shao N; Ma D; Wang J; Lu T; Guo Y; Ji C
    Ann Hematol; 2013 Jan; 92(1):33-9. PubMed ID: 22968660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.